X4 Pharmaceuticals, Inc

The company is a biopharmaceutical business dedicated to creating and commercializing targeted therapies for rare hematological disorders. Its core asset is mavorixafor, an orally administered CXCR4 chemokine receptor antagonist formulated as a capsule. The company markets XOLREMDI (mavorixafor), an FDA-approved prescription medicine for patients aged twelve and older with WHIM syndrome, an ultra-rare primary immunodeficiency and neutropenic condition. In addition to commercializing this therapy, the enterprise is conducting a global Phase 3 clinical trial evaluating mavorixafor for individuals suffering from chronic neutropenia.

The company distributes its approved treatment to patients within the United States through a specialty pharmacy and collaborates with regional partners across international territories, including Europe, the Middle East, North Africa, Australia, New Zealand, and parts of East Asia. Its corporate operations rely on external contract manufacturing organizations, with clinical trials encompassing over one hundred active testing sites internationally, including approximately twenty centers in the United States. The excerpt does not provide the city, state, or country of its headquarters.

Summary of the business section of X4 Pharmaceuticals's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, we had 45 full-time employees.”